Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
54 hedge funds and large institutions have $13.6M invested in Clearside Biomedical in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 20 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 53 → 54 (+1)
1% more call options, than puts
Call options by funds: $221K | Put options by funds: $218K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.18% less ownership
Funds ownership: 1.52% → 1.34% (-0.18%)
32% less capital invested
Capital invested by funds: $20.1M → $13.6M (-$6.52M)
65% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LNC
Lincoln National Corp
Radnor,
Pennsylvania
|
+$135K |
| 2 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
+$39.5K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$32.8K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$25K |
| 5 |
CG
Carmignac Gestion
Paris,
France
|
+$14.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$707K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$505K |
| 3 |
Renaissance Technologies
New York
|
-$218K |
| 4 |
Millennium Management
New York
|
-$214K |
| 5 |
Two Sigma Advisers
New York
|
-$203K |
CLSD Hedge Fund Activity: Q3 2022 in Review
54 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2022, worth a combined $13.6M — down 32% from $20.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CLSD positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 20 trimmed.
The largest buyer was Lincoln National Corp, opening a new position worth an estimated $135K. The largest seller was Morgan Stanley, cutting an estimated $707K.
- 54 institutional investors held Clearside Biomedical (CLSD) as of Q3 2022, up from 53 in Q2 2022.
- Funds reported $13.6M of Clearside Biomedical stock for Q3 2022, down 32% quarter-over-quarter.
- 7 funds opened new Clearside Biomedical positions in Q3 2022 and 6 closed out, a net change of +1 holder.
- The largest Clearside Biomedical buyer in Q3 2022 was Lincoln National Corp, an estimated $135K added.
- The largest Clearside Biomedical seller in Q3 2022 was Morgan Stanley, an estimated $707K sold.
Based on aggregated 13F filings for Q3 2022.